Tags : Acute Kidney Injury

Astellas’ ASP1128 Receives the US FDA’s Fast Track Designation for

Shots: The US FDA has granted FT designation to the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery In 2018, Astellas acquired Mitobridge to focus on developing mitochondrial-directed therapies and recognizes the serious burden of AKI on patients. […]Read More

Baxter Launches PrisMax Acute Care System for Acute Kidney Injury

Shots: Baxter has received the US FDA’s 510 (k) clearance for its PrisMax system and the integrated TherMax blood warmer for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) to treat patients with AKI and other immune diseases PrisMax features TrueVue Analytics tools evaluating the aggregated data, assessing the quality of CRRT program […]Read More

Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney

Shots: Baxter and BioMerieux enter into an agreement to develop biomarkers for identification & treatment for acute kidney injury (AKI) The focus of the agreement is to utilize BioMerieux’s expertise in diagnostics & advancing Baxter’s critical care portfolio including nutrition, renal, hospital and surgical products  Additionally, On April 24, 2018 BioMerieux has acquired Astute Medical […]Read More